Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
PubMed 30097390 ↗Guanfacine
Also known as Intuniv, Tenex
The short answer. More people than not who report on Guanfacine say it helped (71% of 50). It is most often used for focus: 85% of 26 reports say that improved. It is well studied — 53 meta-analyses on PubMed. The most common complaint is drowsiness.
From 105 mentions in total — the rest didn't say how it went and aren't counted.
What Guanfacine does, according to users
Of the people who reported each effect, the share who said it got better.
2 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 53 meta-analyses on PubMed ↗ · 116 randomized trials ↗
Conclusion: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317.
PubMed 35246237 ↗Conclusion: Stimulants and atomoxetine were the only interventions with evidence of beneficial effects in terms of reducing ADHD core symptoms in the short term, supported by both self-reported and clinician-reported ratings. However, atomoxetine was less acceptable than placebo. Medications for ADHD were not efficacious on additional relevant outcomes, such as quality of life, and evidence in the longer term is underinvestigated. The effects of non-pharmacological strategies were inconsistent across different raters. Our network meta-analysis represents the most comprehensive synthesis of available evide
PubMed 39701638 ↗Conclusion: Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu
PubMed 33085721 ↗97 human trials on ClinicalTrials.gov test Guanfacine — 67 completed, 10 recruiting now. See all on ClinicalTrials.gov ↗
- Dexamethasone to Target Stress and Immune System Mechanisms Underlying Alcohol Craving · Alcohol Use Disorder · 2024
- A Trial of Guanfacine-er for Cannabis Use Disorder · Cannabis Use · 2023
- Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents · ADHD · 2024
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
The current US prescription label has no boxed warning.
4 recalls of products named for Guanfacine. Most recent:
- 2021-04-14 · Class II: Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate record ↗
- 2014-01-29 · Class II: Labeling: Label Mixup: guanFACINE HCl, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: buPROPion HCl ER, Tablet, 200 mg,… record ↗
- 2014-01-29 · Class II: Labeling: Label Mixup: guanFACINE HC, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: glyBURIDE, Tablet, 2.5 mg, NDC… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
7,823 adverse-event reports mention Guanfacine. Most often reported:
- Drug ineffective · 813
- Off label use · 630
- Somnolence · 471
- Aggression · 388
- Fatigue · 351
- Hypotension · 299
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Guanfacine E — an unlikely cause of liver injury. LiverTox entry ↗
NIH has funded 21 research projects with Guanfacine in the title, $18,586,928 in total (1985–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Guanfacine ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“It helped so much with rejection sensitivity. I felt braver. Guanfacine is an alpha agonist and decreases norepinephrine/fight and flight response. It takes 3 weeks to kick in and you need to take this every day.”
“I'm on guanfacine after taking stimulants. It's….. better than taking nothing but guanfacine is like a 2 out of 10.”
“Currently i am taking clomipramine and guanfacine which helps for the anxiety and dpdr but makes me sleepy all day.”
“I've tried the traditional ADHD meds like Strattera and Guanfacine, and they don't offer any improvement.”
Top discussions (5)
- Sulforaphane is doing wonders for my ADHD.. Finally some relief ↗
- After one year of biohacking, my brain fog finally cleared. ↗
- Most effective and profoundly noticeable substance for Social Anxiety ↗
- I HAVE TRIED MORE NOOTROPICS THAN YOU. Here are some that I like ↗
- Adderall Risks: Much More Than You Wanted To Know ↗
Other options for focus
Sources
- User reports: 105 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate